Partnering Providers and Services

Click on links or scroll down for full details.

Our partnering providers will choose the recipients of their services from among the 10 companies in the final cohort. Criteria include technology, market potential, and how much a startup would benefit from a particular service. Services must be used within 12 months of final pitch event.

Partnering Providers

Catalent Biologics

One award available. Visit the Catalent Biologics website

Pool generation of one product using GPEx® Cell Line Development technology to be used within 1 year of award date.

About Catalent Biologics

For more than two decades, Catalent Biologics has built capabilities and experience in development, manufacturing, and analytical services for new biological entities, gene therapies, biosimilars, and antibody-drug conjugates. Catalent has worked with 600+ mAbs and 80+ proteins, and 12 biopharmaceutical drugs produced using GPEx® cell line development technology have been approved and marketed, with more than 120 ongoing clinical trials utilizing therapeutic candidates developed using the GPEx platform. A further 25 commercially-approved products have employed Catalent Biologics’ capabilities through to aseptic fill/finish. Catalent’s latest addition, Paragon Gene Therapy, provides industry-leading capabilities and expertise in the development and manufacturing of adeno-associated virus (AAV) vectors, next-generation vaccines and oncolytic virus production.  Its manufacturing facilities in Baltimore, Maryland have produced over 100 GMP batches across 40 clinical and commercial programs. Using advanced technology and tailored solutions for clinical through commercial supply, Catalent Biologics brings better biologic treatments to patients, faster.  

Charles River Laboratories

One award available. Visit the Charles River website

In-Kind Sponsorship Content Description

Evolving Your Program to a Translational Integrated Drug Discovery Program

Consultancy with Charles River Discovery’s Corporate Vice President of Integrated Drug Development and Strategic Projects, John Montana, PhD


  • 2-page scientific background summary

  • Research program summary and target product profile (may be taken from existing business plan or investor presentation deck)

Scope of work

  • Initial program review and assessment conducted by John Montana, PhD, Corporate Vice President, Integrated Drug Development and Strategic Projects, based upon materials provided by principal investigator

  • Gap analysis and recommendations delivered to principal investigator within 4 weeks

  • Written outline of proposed next steps to address gaps and advance the program, including cost estimates where appropriate, for planning purposes

  • Up to two 1-hour phone calls with principal investigator within 4 weeks of receipt of outline (PI may invite additional team members to participate in these calls)

Discovery from Charles River delivers world-class science

Discovery from Charles River is industry-proven in the successful development of novel therapies, with over 350 patents and 80 preclinical drug candidates delivered to our Partners in the past 18 years. Backed by more than 650 scientists, our comprehensive, integrated translational drug discovery approach employs the latest technology and platforms to provide all aspects of chemistry, biology, and pharmacology that support our Partners from the earliest stages of target validation all the way through to IND. Our project-focused, collaborative approach creates true partnerships that anticipate challenges, overcome obstacles, and move us forward together on the journey of getting new drugs to market.

John Montana, CVP Integrated Drug Discovery & Strategic Projects

John Montana, PhD oversees all aspects of partnered integrated drug discovery projects, ensuring their scientific progression from early business development discussions through to established relationships that deliver quality clinical candidates. John came to Charles River from Argenta, where he was Managing Director. Prior to that, he was Director of Research at Chiroscience, then, following the merger of Chiroscience and Celltech, he became Director of NCE Research, with overall responsibility for the company's small molecule portfolio. Dr. Montana is a member of the Royal Society of Chemistry, and his research has appeared in excess of 150 peer-reviewed papers and patents.


CLEO Life Sciences

One award available. Visit the CLEO website

CLEO will provide 12 hours of CMC consulting. A standard client NDA will apply.

About CLEO life sciences

CLEO Life Sciences is a unique hybrid model of Chemistry, Manufacturing, and Controls (CMC) consulting combined with a small-scale R&D prototyping lab for pharmaceutical formulation development. We support clients with nimble prototyping of products and processes, using reduced quantities of API and starting formulation development earlier in the drug development cycle.

CLEO is able to facilitate rapid efficient tech transfers to GMP contract manufacturing sites, troubleshooting, and scale-up. We enable product & process development on highly accelerated timelines and improve management of CMC technical and execution risks.

CLEO has a global network of consultants and relationships with contract manufacturing organizations (CMOs) to integrate or refer the right technical expertise and manufacturing capabilities.

CLEO was incorporated in 2004 in Delaware as a limited liability corporation, and is currently a resident company at Johnson & Johnson Innovation, JLABS @ South San Francisco.


One award available. Visit the Entralta website

Entralta will provide eight hours of pro bono legal in kind services focused on intellectual property strategy.

About Entralta

Entralta understands that you want a firm that treats you like a partner and does not just view you as a client with a pocket book. At the same time, Entralta understands that you want a firm that will avidly work to obtain the best result for its clients, in the shortest period of time, for the most reasonable price. That is what we will do for you and your organization.

As a start, we understand that worldwide procurement and protection of intellectual property is a competitive cornerstone in today’s marketplace. Whether an entrepreneurial start-up founded on a new innovation, a research institute or university holding a diverse array of discoveries, or a multinational corporation possessing a worldwide IP portfolio, we will seamlessly work with you to protect your valuable IP assets in a manner that aligns with your specific commercial objectives. Our highly-regarded, interdisciplinary team of IP attorneys skillfully apply their extensive legal knowledge, insightful technical experience, and sharp business acumen to help you strategically create, develop, manage, and benefit from your IP assets.

We can expertly handle a wide range of intellectual property issues including: 1) procuring, leveraging and enforcing your patents, trademarks, trade dress, copyrights, trade secrets, and other IP assets; 2) advising, negotiating, and shepherding on your behalf the sale, acquisition, merger, enforcement, and licensing of your or a third party’s IP assets; and 3) performing, evaluating, and counseling you regarding due diligence, IP portfolio evaluation, IP valuation, and infringement and validity opinions regarding your or a third party’s IP. Read more on the Entralta website

Fish & Richardson

One award available. Visit the Fish & Richardson website

Up to 8 hours consultation with Teresa Lavoie, J.D., Ph.D., and Caleb Bates, J.D., Ph.D. regarding IP strategy.

About Fish & Richardson

Fish & Richardson, a premier global intellectual property law firm, is sought-after and trusted by the world’s most innovative brands and influential technology leaders. Fish offers patent prosecution, counseling and litigation and trademark and copyright prosecution, counseling and litigation. Our deep bench of attorneys with first-chair trial experience in every technology makes us the go-to firm for the most technically complex cases. We have an established reputation as a top-tier firm for patent portfolio planning, strategy and prosecution, as well as post-grant proceedings at the PTAB. Fish was established in 1878, and now has more than 400 attorneys and technology specialists in the U.S., Europe and China. Our success is rooted in our creative and inclusive culture, which values the diversity of people, experiences and perspectives. For more information, visit or follow us at @FishRichardson.

Illumina Accelerator

One award available. Visit the Illumina Accelerator website

One Illumina Accelerator Sequencing Grant is available to a participating genomics startup. The winner will have the opportunity to spend one week at Illumina Accelerator in the San Francisco Bay Area to run proof-of-concept sequencing experiments. Includes up to $10K worth of Illumina products.

About Illumina Accelerator

At Illumina, we’re committed to unlocking the power of the genome, and we know we can’t do it alone. Illumina Accelerator is our way of accelerating innovation in the entrepreneurial community. With extensive mentorship, financial support, and access to sequencing systems, reagents, and lab space, we are building a dynamic ecosystem to help genomics startups launch in the San Francisco Bay Area. Together, we'll advance breakthrough applications in genomics, including therapeutics, diagnostics, agriculture, synthetic biology, forensics, and direct-to-consumer applications.

Kilpatrick Townsend

One award available. Visit the Kilpatrick townsend website

Kilpatrick Townsend and Stockton will provide three one-hour sessions of IP strategy and counsel with a team including a partner and senior associate from our patent prosecution practice group. We will review your technology and discuss your goals; offer advice as to patent claim strategy, clearance and FTO issues; and outline a strategy to position your company for investors and acquirers.

About Kilpatrick Townsend

We help leaders create, expand, and protect the value of their companies and most prized assets by bringing an equal balance of business acumen, technical skill, and creative thinking to the opportunities and challenges they face.

Our attorneys and staff are committed to our clients’ success. We take the time to understand our clients’ businesses, and work collaboratively with them to achieve their business goals — whether managing complex transactions, tackling global compliance, succeeding in litigation, or protecting their intellectual property. By investing in their success, we have helped clients make their businesses better, smarter, and more protected.

Morrison Foerster

One award available. Visit the Morrison Foerster website

Morrison & Foerster will provide up to 8 hours consultation on venture capital financing and strategic alliances.

About Morrison Foerster

MoFo’s startup lawyers are currently working with approximately 1,000 entrepreneurs, founders, and venture investors. For over four decades, we have advised companies at every stage of the business lifecycle—from initial formation and financings, through late-stage financings and investments, mergers and acquisitions, and public offerings. In just the last five years, we have assisted our clients in venture capital financings totaling over $58 billion, in closing over 40 initial public offerings, and hundreds of mergers and acquisitions with an aggregate transactional value in excess of $660 billion. MoFo has 170+ lawyers located in key global business centers advising startups, emerging and growth companies, and venture capital funds, corporate venture capital clients, and other financing sources. We assist companies with a full range of services, including initial formation and financings, late-stage financings, secondary transactions and investments, mergers & acquisitions, public offerings, strategic alliances and joint ventures, licensing deals, commercial contracts, patent prosecution, executive compensation, labor & employment, and corporate governance.

Nucleo Life Sciences

One award available. Visit the Nucleo website

Toxicology Prototype Development 

  • Review available documentation on Active Pharmaceutical Ingredient to identify lead solvents and surfactants to screen

  • Perform solubility evaluation of lead compound in organic solvents and surfactants screening

  • Evaluate the particle size of API and the influence of particle size in the preparation of a suspension formulation

  • Propose lead prototypes for a PK study (2 lead prototypes)

About Nucleo Life Sciences

Based in the San Francisco Bay Area, Nucleo Life Sciences is a boutique CMO that’s passionate about helping you take your drugs into the clinic—and the market—as quickly and effectively as possible. With our decades of experience in the entire idea-to-commercial-release product cycle, you get a thoughtful and comprehensive proposal at the beginning of the process so there are no surprises. And because we streamline the product-development process, we drastically reduce changes along the way and save you from expensive clinical studies. We believe good communication and project management is as important to the success of a project as good science. Our operations team is deeply involved at every step along the way to keep your project firmly on track.


At least one award available; possibly more, depending on companies in final cohort. Visit the o2h website

o2h is delighted to offer our Start-up Foundation and Accelerator Programmes to the selected partners at QB3 Pitch Summit Event in November 2019 as outlined below:

Start-up Foundation Programme

Medicinal chemistry/Business consultation with Andy Morley, CSO, o2h Limited and Partner at o2h Ventures. This would include:

  • Evaluation of Key compounds/series

  • SAR (if available)

  • IP (evaluation of competitor landscape and view of how IP could be filed, or feedback on IP filing and any additional support work to supplement the IP portfolio)

  • Gap analysis and propose likely profiles of compounds where data isn’t currently available

  • Proposal to reach next milestone: Strategy and plans; Resource; Costs


At the end of the programme, the company/PI should be able to understand

  • Status of project

  • Proposed strengths and weaknesses of key compounds/series

  • Proposed IP strategy

  • Proposed assays/resource/cost/time to reach next key milestone

Start-up Accelerator Programme

Medicinal chemistry/Business consultation with Andy Morley, CSO, o2h Limited and Partner at o2h Ventures. This would include:

Evaluation of Key compounds/series

  • SAR (if available)

  • IP (evaluation of competitor landscape and view of how IP could be filed, or feedback on IP filing and any additional support work to supplement the IP portfolio)

  • Gap analysis and propose likely profiles of compounds where data isn’t currently available

  • Proposal to reach next milestone: Strategy and plans; Resource; Costs

Special one-off discount (up to 25%) to synthetic chemistry support for three months and free 100 ADME points (to conduct ADME assays)


At the end of the programme, the company/PI should be able to understand

  • Status of project

  • Proposed strengths and weaknesses of key compounds/series

  • Proposed IP strategy

  • Proposed assays/resource/cost/time to reach next key milestone

The synthetic chemistry and In-Vitro ADME support may allow further understanding of SAR and strengthening IP position. This can further be expanded/extended to progress the project on need basis.

Requirements for Start-up Foundation and Accelerator Programme

  • Disease areas of interest, biological mechanism of action, any supporting target validation information

  • List of made/tested compounds (including structures) and any results/profiles

  • IP filings (if undertaken)

  • Suggestion of key goals for next milestone

Dr Andy Morley, CSO at o2h Limited

Dr Andy Morley is Chief Scientific Officer for o2h, providing support to all aspects of the organisation over the last seven years. Dr Morley previously spent >20 years in large pharma (Sanofi-Aventis and AstraZeneca) working across all phases of pre-clinical discovery. He is author and inventor on >50 patents and publications.  He has supported the progression of 5 candidates into clinical development. Dr Morley obtained his Ph D working with Garry Procter, followed by postdoctoral studies with Nobel Prize winner Professor Ryoji Noyori at the University of Nagoya, Japan. Andy Morley LinkedIn Profile

About o2h

o2h Discovery has been supporting small molecule drug discovery projects since 2003. We have partnered with a range of well-known pharmaceutical and biotechnology companies from Europe, USA and Japan. The organisation has emerging office and wet lab capabilities in the o2h Mill Park in Cambridge, UK and employs 250 people.  During our 15+ years in business we have started, exited and rebuilt the business post non-compete (2011), trained over 1,000 chemists globally, used the services platform to build an ecosystem to support early stage drug discovery and/or fledgling biotech companies with more than just research services to include funding (the o2h therapeutics fund and Founders Angel Investments) into around 20 companies so far.  o2h have acquired a 2.7 acre site located next to Addenbrookes and AstraZeneca and will provide high end biology services from here as well as incubation space for fledgling biotech, and business support and mentoring.

o2h Discovery started life as a synthetic chemistry provider. Although this remains a core part of the business, we have extended our services to medicinal chemistry and designer expertise, kilo lab, ADME, primary and secondary screening assays and moving forward a fragment based discovery approach to identifying hits. o2h can provide end-end support for discovery projects with in vivo partners that they have.

o2h has built a 20+ person technology team.  We believe that through technology we can create massive differentiation in drug discovery services. Given the founders background in technology through their first start-up we have always been looking to use this as an advantage.  We have recently developed our proprietary project management app AI-Chemistry in the Cloud™ which provides fully integrated and real time information around every aspect of a collaboration, new modules soon to go live which are fully integrated include ADME module, our ELN (designed by chemists for chemists), digitization of local starting material suppliers in India.


Three awards available. Visit the Repositive website

Cancer Models Scout  [download full description]

Repositive’s Cancer Models Scout is a bespoke service to you to source the right preclinical models and services for your next research project.  We specialize in providing model recommendations tailored to each project’s precise requirements throughsearching not only Repositive's world-leading directory of models, but also an extended CRO network containing over 20,000 models. Our bioinformatics team can conduct complex genomic and molecular analyses of models to find those that will be most predictive of patient response. In the end, we deliver a comprehensive report outlining the best available models for each study.

About Repositive

Repositive is the world’s largest directory of preclinical cancer models, cataloguing the metadata for over 5,300 PDX and CDX models, syngeneic and humanized mouse models, GEMMs, cell lines and organoids, from specialist oncology CROs around the world.  Start exploring Repositive’s online directory today and let its experts find the right model for your project in just a matter of weeks, de-risking your preclinical program and boosting your pipeline’s productivity. Access Repositive’s Cancer Models Platform here: 

Young Basile

Two awards available. Visit the Young Basile website

Senior Counsel Sunil Singh will provide at least 10 hours of consultation on your company’s IP landscape.

About Young Basile

Young Basile is an intellectual property and litigation firm that represents leading global companies, regional technology-driven companies and emerging businesses. With a combination of deep technical knowledge and business acumen, we drive successful results for our clients’ most important and complex matters. We deliver extraordinary value while advancing our clients’ strategic business objectives.